

About Us

Sucampo Pharmaceuticals is a specialty biopharmaceutical company focused on the development and commercialization of drugs based on prostones, which are bio-lipids that occur naturally in the human body. In January 2006, the FDA approved Sucampo's first product, AMITIZA® (lubiprostone), (24 mcg) for Chronic Idiopathic Constipation in adults and in April 2008 approved the product for Irritable Bowel Syndrome with Constipation (8 mcg). The company is marketing AMITIZA® (lubiprostone) 24 mcg for CIC in adults and 8mcg for IBS-C in women 18 years of age and older, and is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, the company has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide.

AMITIZA®: A New Medicine for Chronic Constipation



AMITIZA® (lubiprostone) is Sucampo's FDA-approved drug for the treatment of chronic idiopathic constipation in adults of all ages. AMITIZA is the #1 branded prescription product for chronic idiopathic constipation.

AMITIZA was launched in the United States in April 2006, and is co-marketed by Sucampo's institutional sales force and partner, Takeda Pharmaceutical Company Limited. Our national TV advertising campaign for AMTIZA "Move to AMITIZA" is currently on-going. Look for it on local stations.



Established Sales Force Infrastructure

Sucampo has an established sales force that focuses on the institutional and long-term care markets. Sucampo has been recognized as a top 20 pharmaceutical company in promoting to the U.S. nursing home market in a spring 2007 survey by Verispan, alongside other global pharmaceutical companies. Our strategy to target the long-term care market with products to treat diseases affecting an aging population complements our focus of treating particular indications in the elderly population.

Focused Growth Strategy

- Expand the U.S. market for AMITIZA
- Develop and commercialize AMITIZA for additional indications
- Pursue approval and marketing of AMITIZA and other candidates in Europe and Asia-Pacific
- Focus resources for our core discoveries and clinical development and commercialization activities
- Grow through strategic acquisitions and in-licensing opportunities
- Develop and commercialize pipeline of additional prostone-based compounds

Pipeline Builds on our Core Prostone Technology


Sucampo is building a pipeline of clinical candidates designed to leverage the strength of its discovery and development experience with prostones. Additional compounds in development include:

- **Cobiprostone (SPI-8811)** for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, and disorders associated with cystic fibrosis and chronic obstructive pulmonary disease.
- **SPI-017** for the treatment of peripheral arterial and vascular disease and central nervous system disorders. Sucampo is working on the development of an intravenous formulation of SPI-017 for the treatment of peripheral arterial disease, and developing an oral formulation of SPI-017 for the treatment of Alzheimer's disease.

Sucampo Snapshot

Ticker:	SCMP
Listing:	NASDAQ GM
IPO Date:	August 2, 2007
Shares Outstanding:	41.7 Mil

Product Pipeline



Near-Term Milestones

AMITIZA

- ✓ Approved sNDA for IBS-C
- ✓ Commercial launch of Amitiza 8 mcg for IBS-C
- ✓ Initiated Phase IV study in chronic idiopathic constipation (pediatric)
- ✓ Completed Phase IV study in renal impairment
- ✓ Initiated Phase IV study in hepatic impairment
- ✓ Initiated Phase III study in Opioid Induced Bowel Dysfunction (OBD)
- ✓ Internalized Sucampo sales force
- ✓ European agencies initiate review of lubiprostone

SPI-8811

- ✓ Completed Phase II study in NSAID-induced ulcers
- Initiate Phase II study in portal hypertension

SPI-017

- Initiate Phase I study (i.v. formulation)
- Initiate Phase I study (oral formulation)

Corporate Officers

Ryuji Ueno, M.D., Ph.D., Ph.D.
Founder, Chief Executive Officer,
Chief Scientific Officer and
Chairman of the Board of
Directors

Mariam E. Morris, CPA
Chief Financial Officer and
Treasurer and Secretary

Brad Fackler, MBA
Executive Vice President,
Commercial Operations

Gayle Robert Dolecek, P.D., M.P.H.
Senior Vice President,
Research and Development

Jan Smilek, CPA
Chief Accounting Officer, Vice
President of Finance and
Corporate Controller

Investor Relations Contact:
Mariam E. Morris
Chief Financial Officer
Phone: +01-301-961-3400
Fax: +01-301-961-3440
mmorris@sucampo.com

This fact sheet contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include without limitation, statements regarding near-term R&D milestones and other statements that may be identified by words such as "expectations," "remains," "focus," "expected," "prospective," "expanding," "building," "continue," "progress," "efforts," "hope," "believe," "objectives," "opportunities," "will," "seek," and other expressions which are predictions of or indicate future events and trends and which do not constitute historical matters identify forward-looking statements. The statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and other factors. The Company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors. Certain factors that might cause the Company's actual results to differ materially from those in the forward-looking statements include those set forth under the heading "Risk Factors" in Sucampo Pharmaceuticals' Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended December 31, 2007 and its Quarterly Report on Form 10-Q filed subsequently.